1. Home
  2. TORO vs ENTX Comparison

TORO vs ENTX Comparison

Compare TORO & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Toro Corp.

TORO

Toro Corp.

N/A

Current Price

$6.06

Market Cap

174.5M

ML Signal

N/A

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

N/A

Current Price

$2.94

Market Cap

147.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TORO
ENTX
Founded
2022
2010
Country
Cyprus
Israel
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.5M
147.4M
IPO Year
2022
2015

Fundamental Metrics

Financial Performance
Metric
TORO
ENTX
Price
$6.06
$2.94
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$9.00
AVG Volume (30 Days)
25.0K
344.3K
Earning Date
04-15-2026
05-14-2026
Dividend Yield
36.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.22
Revenue
N/A
$42,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$13.50
Revenue Growth
N/A
N/A
52 Week Low
$2.95
$0.91
52 Week High
$8.50
$4.20

Technical Indicators

Market Signals
Indicator
TORO
ENTX
Relative Strength Index (RSI) 47.95 49.61
Support Level $4.87 $2.73
Resistance Level $6.15 $3.10
Average True Range (ATR) 0.27 0.18
MACD -0.08 -0.02
Stochastic Oscillator 20.03 45.74

Price Performance

Historical Comparison
TORO
ENTX

About TORO Toro Corp.

Toro Corp is engaged in the acquisition, ownership, chartering, and operation of oceangoing tanker and LPG carrier vessels, providing seaborne transportation services for crude oil, refined petroleum products, and liquefied petroleum gas. The company operates through three segments: the Eco tanker segment, the Non-Eco tanker segment, and the LPG carrier segment. It generates the majority of its revenue from the LPG carrier segment.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: